Encore Therapeutics Inc. Reports Additional Proof of Concept Results on its Extended Release Ropivacaine Injectable Gel for Postoperative Pain Management

Published: Aug 02, 2007

CARLSBAD, Calif.--(BUSINESS WIRE)--ETI today reported on two pre-clinical studies demonstrating that its intradermal extended release Ropivacaine gel formulation (ETI-211) has a markedly improved safety and pharmacokinetic (PK) profile when compared to the currently marketed ropivacaine solution formulation.

Back to news